Journal Information
Vol. 28. Issue. 2.April 2008
Pages 123-238
Vol. 28. Issue. 2.April 2008
Pages 123-238
Full text access
Use of vascular polyurethane-urea prosthesis of the of the vectra type in a hemodialysis unit
Experiencia en el uso de prótesis vasculares de poliuretanurea tipo Vectra en una unidad de hemodiálisis
Vicente Esteve Simóa, M.. Poua, M.. Ramírez de Arellanoa, F.. Latorreb
a Servei de Nefrología, Consorci Sanitari de Terrassa, Terrassa, Barcelona, España,
b Servei de Cirugia Vascular, Consorci Sanitari de Terrassa, Terrassa, Barcelona, España,
This item has received
Article information
Full Text
Download PDF
Full Text

To the editor:

The internal native arteriovenous fistula (IAVF) is the elective vascular access in patients with chronic renal failure on hemodialysis.1 In case that the performance of a native access is impossible due to difficulties with the vascular bed, the vascular grafts constitute an efficacious alternative.2

The new polyurethane-urea prosthesis of the VECTRA type has a stiffer wall than those composed of polytetrafluorethylene (PTFE).3-5 This characteristic allows using it within the first days after placement, avoiding so the use of temporary catheters and their potential complications.6-8

In the last two years the VECTRA prosthesis have been employed in our Hemodialysis Unit in those patients with absent or difficult vascular access, who needed hemodialysis in the short term. We briefly describe our experience with the use of this type of vascular prosthesis, as well as their main characteristics, the evolution and the complications associated to their use.

Between January of 2005 and March of 2007 a total of 7 VECTRA prosthesis were placed in 6 patients (50% males), mean age 56.1 years and mean time on hemodialysis 98.6 months. The most frequent etiology of the ESRD was diabetes mellitus in 2 patients (33%). Other underlying conditions were high blood pressure (100%), ischemic heart disease and peripheral vascular disease (66%), and diabetes (33%). Mean Charlson¿s index was 7. In each patient the mean number of previous vascular access was 4.2 (32% IAVF, 32% temporary catheters, 20% funneled catheters, and 16% PTFE prosthesis). VECTRA prostheses were mainly placed at the femoral level in 42% of the cases. Mean time for the first puncture was 10.4 days, and the initial puncture was performed within the first 96 hours of graft placement in 58% of the cases. The following complications were registered: one serious hematoma during initial puncture, 6 thromboses of the prosthesis (85%), in 3 patients being immediate (first 7 days), and 1 pseudoaneurysm (14%) as a late complication. A surgical thrombectomy was performed that was effective, and 2 temporary catheters were placed to treat the complications. Only one prosthesis works to date, the mean working time of the thrombosed grafts being 30.5 days (5 cases). One patient received a renal transplant from a cadaver donor, which is still functioning, and during the study period 5 patients died from causes not related to the vascular access.

In our limited experience, the use of VECTRA type prosthesis allowed hemodialysis within the first days after placement in more than half of the cases, but early thrombosis was the most important complication with this type of prosthesis. With these results, the placement of these grafts should be limited to patients with no native IAVF because of difficult vascular accesses, who require not urgent shortterm renal replacement therapy.

NFK-DOQI (Nacional Kidney Foundation - Kidney Disease Outcomes Quality Initiatives). Clinical Practice Guidelines for Vascular Access. Guideline No 9. Update 2000.
Tordoir JH, Hosftra L, Leunissen KM, Kistaar PJ. Early experience with stretch polytetrafluorethylene grafts for haemodialysis access surgery: results of a prospective randomized study. Eur J Vasc Endovasc Surg 1995; (9): 305-9.
Instructions for use for Vectra vascular access graft. Thoratec laobratories Corporation. December 2000.
Glickman MH y cols. Multicenter evaluation of a new polyurethanurea vascular access graft compared with the expanded polytetrafluorethylene vascular access graft in haemodialysis applications. J Vasc Surg 2001; 34: 465-72.
Nakao y cols. Creation and use of polyurethane- expanded polytetrafluoro-ethylene graft for hemodialysis access. Acta Med Okayama 2000; 54: 91-94. [Pubmed]
Jefic D, Reddy P, Flyn LM, Provenzano R. A single center experience in the use of polyurethanurea arteriovenous grafos. Neprhol News Issues 2005; 19 (8): 44-7.
Hakaim AG, Scott TE. Durability of early prosthetic dialysis grafts cannulation: results of a prospective nonrandomized clinical trial. J Vasc Surg 1997; 25: 1002-5, discusión 1005-6.
Coyne DW, Lowell JA, Windus DW, Delmez JA, Shenoy S, Audrain J y cols.: Comparasion of survival of an expanded polytetrafluorethylene grafo designed for early cannulation to standard wall polytetrafluoro- ethylene grafos. J Am Coll Surg 1996; 183: 401-5. [Pubmed]
Nefrología (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?